Pages that link to "Q35597348"
Jump to navigation
Jump to search
The following pages link to Risk of haematopoietic cancer in patients with inflammatory bowel disease (Q35597348):
Displaying 50 items.
- Cancer in inflammatory bowel disease (Q24648315) (← links)
- MANAGEMENT OF ENDOCRINE DISEASE: Epidemiology, quality of life and complications of primary adrenal insufficiency: a review (Q26749248) (← links)
- Rare gastrointestinal lymphomas: The endoscopic investigation (Q26799041) (← links)
- Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes (Q27015288) (← links)
- Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature (Q33691577) (← links)
- Anaplastic large cell lymphoma of the colon in a patient with colonic Crohn disease treated with infliximab and methotrexate (Q33810149) (← links)
- Summary of worldwide pediatric malignancies reported after exposure to etanercept (Q33998050) (← links)
- Do inflammatory bowel disease therapies cause cancer? (Q34613890) (← links)
- Epidemiology of cancer of the small intestine (Q34628138) (← links)
- Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer (Q34637366) (← links)
- Clinical epidemiology--how important now? (Q35597321) (← links)
- Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study (Q35637884) (← links)
- Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota (Q35690314) (← links)
- Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study (Q35761047) (← links)
- Co-existence of Crohn's disease, sarcoidosis and malignant lymphomas (Q35793881) (← links)
- Acute myeloid leukemia developing in patients with autoimmune diseases (Q36006358) (← links)
- Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium (Q36528740) (← links)
- Medical conditions and risk of adult myeloid leukemia. (Q36608364) (← links)
- Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? (Q36811485) (← links)
- Immune surveillance and lymphoid malignancy in immunocompromised host (Q36831205) (← links)
- Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? (Q36864836) (← links)
- Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes (Q36939427) (← links)
- Hyaline-Vascular Type Castleman's Disease, Sarcoidosis, and Crohns Disease (Q37048421) (← links)
- Treatment of inflammatory bowel disease: a review of medical therapy (Q37058862) (← links)
- Risks of myeloid malignancies in patients with autoimmune conditions (Q37123507) (← links)
- Cancer risk in immune-mediated inflammatory diseases (IMID). (Q37153407) (← links)
- Adalimumab in Crohn's disease (Q37290464) (← links)
- Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations (Q37492482) (← links)
- Managing the risks of IBD therapy (Q37630746) (← links)
- Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease (Q37656048) (← links)
- Optimizing the safety of biologic therapy for IBD. (Q37687869) (← links)
- Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies (Q37717996) (← links)
- Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts (Q37781314) (← links)
- Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications. (Q37875963) (← links)
- Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease (Q37975464) (← links)
- Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease (Q37978252) (← links)
- T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study (Q38049119) (← links)
- Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review (Q38055211) (← links)
- Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature (Q38073582) (← links)
- The role of inflammation in leukaemia (Q38211084) (← links)
- Enteropathy-associated T-cell lymphoma presenting with gastrointestinal tract symptoms: A report of two cases and review of diagnostic challenges and clinicopathological correlation (Q38222754) (← links)
- Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. (Q38253832) (← links)
- Safety considerations when using anti-TNFα therapy to treat Crohn's disease (Q38268598) (← links)
- Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events (Q38394816) (← links)
- Azathioprine-associated myelodysplastic syndrome in two patients with ulcerative colitis (Q38609110) (← links)
- A case of rapid growing colonic NK/T cell lymphoma complicated by Crohn's disease (Q39233164) (← links)
- IBD-related carcinoma and lymphoma (Q39741804) (← links)
- Educational level and occupation as risk factors for inflammatory bowel diseases: A nationwide study based on hospitalizations in Sweden (Q39865364) (← links)
- The etiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections (Q40056500) (← links)
- A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. (Q40513902) (← links)